HVTN 704/HPTN 085, or the AMP (Antibody Mediated Prevention) Study, is a five-year study testing the safety, tolerability, and prevention benefit of an experimental manufactured antibody (VRC01) against HIV. The study enrolled and followed 2,700 men and transgender...
Study of Heterologous Vaccine Regimen to prevent HIV-1 Infection among Cis-gender Men and Transgender Individuals who have Sex with Cis-gender Men and/or Transgender Individuals Web Links: https://clinicaltrials.gov/ct2/show/NCT03964415...
A Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of combinations of monoclonal antibodies administered via intravenous infusion in healthy, HIV-uninfected adults Web Links:...
ICAP conducted this study to develop and follow a cohort of HIV-infected adults starting ART at health facilities across Kenya to understand the levels of inflammatory and coagulation biomarkers in clients and the effect of ART on those...
In close partnership with the Myanmar National AIDS Program (NAP) and the Centers for Disease Control and Prevention (CDC), ICAP evaluated the introduction of a key populations (KP) sensitization training for health care workers and the implementation of structural...
